Four out of 10 eczema patients struggle with sleep, and they may not volunteer that information unless you ask.

Regeneron’s shares have dropped sharply since peaking in August 2024, hurt by slowing Eylea sales due to competition from ...

With multiple novel therapies expected and the treatment paradigm shifting toward earlier intervention, the market will grow ...

Rothschild & Co Redburn initiated coverage of Regeneron (REGN) with a Buy rating and $890 price target Published first on TheFly – the ultimate ...

Dupilumab may provide a nonsteroidal option for managing cancer therapy-related skin toxicities, according to a study.

The SBB Research Group Foundation named Danielle Wang a recipient of its STEM scholarship. The $2,500 award empowers students ...

A patient has died from kidney injury in a trial of ’ lead antibody-drug conjugate, although the biotech has been advised to ...

In July 2025, Merck Sharp & Dohme LLC announced a substudy is to assess the efficacy and safety of ifinatamab deruxtecan ...

In major recent developments, a confidentiality request was rejected, Samsung and its representative A&O Shearman secured a ...

Reports continued progress in the evaluation of assets for potential pipeline expansion in the areas of oncology and rare disease; transaction targeted for 2025 -- ...

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter ...

Reports continued progress in the evaluation of assets for potential pipeline expansion in the areas of oncology and rare disease; transaction t ...